Recombinant C1 Esterase Inhibitor Half-Life Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant human C1 esterase inhibitors, such as Ruconest, have a short half-life due to differences in glycosylation profiles compared to human plasma-derived C1-INH, limiting their efficacy and requiring frequent administration.
Innovation Solution
Development of long-acting recombinant human C1 esterase inhibitors (rhC1-INH) with a half-life comparable to or exceeding that of plasma-derived C1-INH, achieved through optimized glycosylation profiles and production in host cells that enhance sialylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If recombinant C1-INH is produced in non-human host cells (e.g., rabbits), then production cost and scalability are improved, but the glycosylation profile becomes non-human-like resulting in extremely short half-life
Solution Approach 1:
The patent applies parameter changes by modifying the glycosylation state of the recombinant C1-INH protein. Specifically, it produces both sialylated and non-sialylated forms and demonstrates that sialylation is the critical parameter determining serum half-life. The invention identifies that achieving human-like sialylation patterns in non-human host cells is the key to resolving the contradiction between scalable production and extended half-life.
2Duration of action of moving object
If human plasma-derived C1-INH is used, then glycosylation profile and serum half-life are optimized, but supply is limited by blood donation availability and carries infectious disease risk
Solution Approach 1:
The patent applies the copying principle by creating recombinant C1-INH proteins that copy the essential functional and structural characteristics of human plasma-derived C1-INH, including the amino acid sequence and glycosylation patterns. By using human C1-INH cDNA as a template for recombinant expression in mammalian cells, the invention produces a synthetic copy that mimics the natural protein's properties while eliminating dependence on plasma donations and reducing infectious disease risk.
3Ease of manufacture
If recombinant C1-INH with non-human glycosylation is used, then manufacturing cost is reduced, but immunogenicity and hypersensitivity reactions increase
Solution Approach 1:
The patent applies parameter changes by focusing on the glycosylation state as the critical variable. It demonstrates that achieving human-like sialylation patterns in recombinant proteins produced in non-human host cells is essential to minimize immunogenicity. The invention shows that the degree and type of sialylation directly influence both half-life and immunogenicity, making it the key parameter to control for reducing hypersensitivity reactions while maintaining cost-effective manufacturing.
Data Source
AI summary
The present invention provides, among other things, methods and compositions for treating complement mediated disease. In some embodiments, recombinant human C1 esterase inhibitor proteins having similar or longer half-life than native plasma-derived human C1 esterase inhibitor, and methods of making the same are provided. In some embodiments, the invention provides a method for administering an effective amount of a recombinant human C1 esterase inhibitor protein to an individual who is suffering from or susceptible to a complement-mediated disease such that at least one symptom or feature of said complement-mediated disease is prevented and/or reduced in intensity, severity, or frequency.